A phase I/II study of the selective phosphatidylinositol 3-kinase-delta (PI3Kδ) inhibitor, GS-1101 (CAL-101), with ofatumumab in patients with previously treated chronic lymphocytic leukemia (CLL).
Year: 2012
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Richard R. Furman, Jacqueline Claudia Barrientos, Jeff Porter Sharman, Sven De Vos, John Leonard, Steven E. Coutre, Marshall T. Schreeder, Nina D. Wagner-Johnston, Thomas E. Boyd, Nathan Hale Fowler, Ian W. Flinn, Ralph V. Boccia, Leanne Holes, Brian Joseph Lannutti, Dave Johnson, Thomas Michael Jahn, Langdon L. Miller
Institutions: Weill Cornell Medicine, Long Island Jewish Medical Center, Willamette Valley Cancer Institute and Research Center, University of California, Los Angeles, Los Angeles Medical Center, Stanford Medicine, Stanford University, Clearview Cancer Institute, Washington University in St. Louis, Virginia Mason Memorial, The University of Texas MD Anderson Cancer Center, Sarah Cannon, Tennessee Oncology, Center for Cancers and Blood Disorders, Gilead Sciences (United States)
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2471878594